Cancer-related inflammation and treatment effectiveness

Diakos, Connie I.; Charles, Kellie A.; McMillan, Donald C.; Clarke, Stephen

doi:10.1016/s1470-2045(14)70263-3

Cited by 1,697 publications

(1,491 citation statements)

References 87 publications

Supporting

Mentioning

1,370

Contrasting

Unclassified

Order By: Relevance

“…Firstly, it would suggest a role for inhibitors of the IL-6/JAK/STAT3 pathway in restoring anti-tumour immune responses in patients with colorectal cancer (48,49). Secondly, it would support the hypothesis that routine markers of the systemic inflammatory response, and in particular the mGPS, may aid in the identification and selection of patients likely to benefit from such targeted therapies (50). In keeping with such a scheme, one recent clinical trial of a JAK inhibitor in patients with metastatic pancreatic cancer found an increase in overall survival only in those patients with an elevated CRP or mGPS (51).…”

Section: P=0039)mentioning

confidence: 88%

Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host

Park

Wyk

McMillan

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

(2017) Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host. Clinical Cancer Research, 23(7), pp. 1698 -1709 . (doi:10.1158 /1078 -0432.CCR-16-1416 This is the author's final accepted version.There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.http://eprints.gla.ac.uk/129347/ Experimental DesignImmunohistochemical assessment of STAT3/pSTAT3 expression was performed using a tissue microarray and tumour cell expression divided into tertiles using the weighted histoscore. The relationship between STAT3/pSTAT3 expression and local inflammatory The combination of nuclear STAT3/pSTAT3 stratified five-year survival from 81% to 62% (P=0.012), however was not associated with survival independent of venous invasion, tumour perforation or tumour budding. ConclusionIn patients undergoing CRC resection, STAT3 expression was associated with adverse host inflammatory responses and reduced survival. Up-regulation of tumour STAT3 may be an important mechanism whereby the tumour deregulates local and systemic inflammatory responses.5

show abstract

Section: P=0039)mentioning

confidence: 88%

Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host

Park

Wyk

McMillan

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Inflammation makes a significant contribution to carcinogenesis and progression of malignancies [42] . In some conditions, inflammation such as chronic atrophic gastritis is defined as a precancerous lesion of GC.…”

Section: Inflammatory Diseasementioning

confidence: 99%

Role of microRNA-7 in digestive system malignancy

Chen¹

2016

WJGO

View full text Add to dashboard Cite

There are several malignancies of the digestive system (including gastric, pancreatic and colorectal cancers, and hepatocellular carcinoma), which are the most common types of cancer and a major cause of death worldwide. MicroRNA (miR)-7 is abundant in the pancreas, playing an important role in pancreatic development and endocrine function. Expression of miR-7 is downregulated in digestive system malignancies compared with normal tissue. Although there are contrasting results for miR-7 expression, almost all research reveals that miR-7 is a tumor suppressor, by targeting various genes in specific pathways. Moreover, miR-7 can target different genes simultaneously in different malignancies of the digestive system. By acting on many cytokines, miR-7 is also involved in many gastrointestinal inflammatory diseases as a significant carcinogenic factor. Consequently, miR-7 might be a biomarker or therapeutic target gene in digestive system malignancies.

show abstract

“…Findings from recent studies of different malignant tumors have suggested that increases in the levels of systemic inflammation are indicative of poor survival [23,24] . Inflammatory cells within the tumor microenvironment play important roles in tumor development and in the survival of malignant cells [25,26] .…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

Lee¹,

Lee²,

Hyun³

et al. 2016

WJGO

View full text Add to dashboard Cite

AIM:To evaluate the value of systemic inflammationbased markers as prognostic factors for advanced pancreatic cancer (PC). METHODS:Data from 82 patients who underwent combination chemotherapy with gemcitabine and erlotinib for PC from 2011 to 2014 were collected retrospectively. Data that included the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio, and the C-reactive protein (CRP)-to-albumin (CRP/Alb) ratio were analyzed. Kaplan-Meier curves, and univariate and multivariate Cox proportional hazards regression analyses were used to identify the prognostic factors associated with progression-free survival (PFS) and overall survival (OS). RESULTS:The univariate analysis demonstrated the prognostic value of the NLR (P = 0.049) and the CRP/ Alb ratio (P = 0.047) in relation to PFS, and a positive relationship between an increase in inflammation-based markers and a poor prognosis in relation to OS. The multivariate analysis determined that an increased NLR (hazard ratio = 2.76, 95%CI: 1.33-5.75, P = 0.007) is an independent prognostic factor for poor OS. There was no association between the PLR and the patients' prognoses in those who had received chemotherapy that comprised gemcitabine and erlotinib in combination. The Kaplan-Meier method and the log-rank test determined significantly worse outcomes in relation to PFS and OS in patients with an NLR > 5 or a CRP/Alb ratio > 5. CONCLUSION:Systemic inflammation-based markers, including increases in the NLR and the CRP/Alb ratio, may be useful for predicting PC prognoses.

show abstract

Cancer-related inflammation and treatment effectiveness

Cited by 1,697 publications

References 87 publications

Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host

Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host

Role of microRNA-7 in digestive system malignancy

Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

Contact Info

Product

Resources

About